Print this page
-
An Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of XL309 (ISM3091) as Single-Agent and Combination Therapy in Patients with Advanced Solid Tumors.
Protocol: 052404Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors.
Protocol: 052409Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/1b Open-Label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors.
Protocol: 052410Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR).
Protocol: 052407Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/1b Study of IAM1363 in Participants with Advanced Cancers Harboring HER2 Alterations.
Protocol: 052501Principal Investigator:
- Coral Omene
Applicable Disease Sites: Any Site -
Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors.
Protocol: 052409Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 in Participants with Advanced Solid Tumors.
Protocol: 052503Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/1b Open-Label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors.
Protocol: 052410Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/1b Study of IAM1363 in Participants with Advanced Cancers Harboring HER2 Alterations.
Protocol: 052501Principal Investigator:
- Coral Omene
Applicable Disease Sites: Any Site -
A Dose Escalation and Expansion Study of XB371 Administered in Participants with Locally Advanced or Metastatic Solid Tumors
Protocol: 052504Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 in Participants with Advanced Solid Tumors.
Protocol: 052503Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/2, Open-Label, Multicenter, Dose-Escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants with Advanced Solid Tumors.
Protocol: 052505Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Dose Escalation and Expansion Study of XB371 Administered in Participants with Locally Advanced or Metastatic Solid Tumors
Protocol: 052504Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability,
Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination
Therapy in Participants with KRAS-Altered Advanced or Metastatic Solid Tumors
Protocol: 052506Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/2, Open-Label, Multicenter, Dose-Escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants with Advanced Solid Tumors.
Protocol: 052505Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability,
Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination
Therapy in Participants with KRAS-Altered Advanced or Metastatic Solid Tumors
Protocol: 052506Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site